Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 209

  • Showing results for villani l. Search instead for Villagi L (1 item)
1.

Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.

Troncone M, Cargnelli SM, Villani LA, Isfahanian N, Broadfield LA, Zychla L, Wright J, Pond G, Steinberg GR, Tsakiridis T.

Oncotarget. 2017 Apr 27;8(34):57733-57754. doi: 10.18632/oncotarget.17496. eCollection 2017 Aug 22. Review.

2.

Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.

Barosi G, Massa M, Campanelli R, Fois G, Catarsi P, Viarengo G, Villani L, Poletto V, Bosoni T, Magrini U, Gale RP, Rosti V.

Leuk Res. 2017 Sep;60:18-23. doi: 10.1016/j.leukres.2017.06.004. Epub 2017 Jun 7.

PMID:
28622624
3.

The Relationships between HER2 Overexpression and DCIS Characteristics.

Di Cesare P, Pavesi L, Villani L, Battaglia A, Da Prada GA, Riccardi A, Frascaroli M.

Breast J. 2017 May;23(3):307-314. doi: 10.1111/tbj.12735. Epub 2016 Dec 10.

PMID:
27943525
4.

The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration.

Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, Houde VP, Muti P, Tsakiridis T, Steinberg GR.

Mol Metab. 2016 Aug 26;5(10):1048-56. doi: 10.1016/j.molmet.2016.08.014. eCollection 2016 Oct.

5.

Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis.

Massa M, Campanelli R, Fois G, Villani L, Bonetti E, Catarsi P, Poletto V, Viarengo G, De Amici M, Rosti V, Gale RP, Barosi G.

Blood. 2016 Sep 22;128(12):1660-2. doi: 10.1182/blood-2016-03-704577. Epub 2016 Aug 16. No abstract available.

6.

AurkA controls self-renewal of breast cancer-initiating cells promoting wnt3a stabilization through suppression of miR-128.

Eterno V, Zambelli A, Villani L, Tuscano A, Manera S, Spitaleri A, Pavesi L, Amato A.

Sci Rep. 2016 Jun 24;6:28436. doi: 10.1038/srep28436.

7.

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.

Campanelli R, Fois G, Catarsi P, Poletto V, Villani L, Erba BG, Maddaluno L, Jemos B, Salmoiraghi S, Guglielmelli P, Abbonante V, Di Buduo CA, Balduini A, Iurlo A, Barosi G, Rosti V, Massa M; AGIMM Investigators.

PLoS One. 2016 Jun 9;11(6):e0156990. doi: 10.1371/journal.pone.0156990. eCollection 2016.

8.

84P Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside.

Tsakiridis T, Villani L, Marcinko K, Pond G, Wright J, Steinberg G.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S91. doi: 10.1016/S1556-0864(16)30197-6. Epub 2016 Apr 15. No abstract available.

9.

Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.

Rosti V, Campanelli R, Massa M, Viarengo G, Villani L, Poletto V, Bonetti E, Catarsi P, Magrini U, Grolla AA, Travelli C, Genazzani AA, Barosi G.

Am J Hematol. 2016 Jul;91(7):709-13. doi: 10.1002/ajh.24388. Epub 2016 May 26.

10.

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.

Barosi G, Klersy C, Villani L, Bonetti E, Catarsi P, Poletto V, Campanelli R, Impera S, Latagliata R, Viarengo G, Carolei A, Massa M, Musso M, Crescimanno A, Gale RP, Rosti V.

Leukemia. 2016 Aug;30(8):1772-5. doi: 10.1038/leu.2016.45. Epub 2016 Feb 29. No abstract available.

PMID:
26975727
11.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G; SOFT and TEXT Investigators and International Breast Cancer Study Group.

Breast Cancer Res Treat. 2015 Nov;154(2):275-86. doi: 10.1007/s10549-015-3612-z. Epub 2015 Oct 22.

12.

Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.

O'Brien AJ, Villani LA, Broadfield LA, Houde VP, Galic S, Blandino G, Kemp BE, Tsakiridis T, Muti P, Steinberg GR.

Biochem J. 2015 Jul 15;469(2):177-87. doi: 10.1042/BJ20150122. Epub 2015 May 5.

PMID:
25940306
13.

JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.

Catarsi P, Rosti V, Morreale G, Poletto V, Villani L, Bertorelli R, Pedrazzini M, Zorzetto M, Barosi G; AGIMM investigators.

PLoS One. 2015 Jan 24;10(1):e0116636. doi: 10.1371/journal.pone.0116636. eCollection 2015.

14.

ER-alpha and ER-beta expression in differentiated thyroid cancer: relation with tumor phenotype across the TNM staging and peri-tumor inflammation.

Magri F, Capelli V, Gaiti M, Villani L, Zerbini F, La Manna L, Rotondi M, Chiovato L.

Endocrine. 2015 Jun;49(2):429-35. doi: 10.1007/s12020-014-0457-x. Epub 2014 Oct 22.

PMID:
25338203
15.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators.

Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1.

16.

Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age.

Denegri M, Bongianino R, Lodola F, Boncompagni S, De Giusti VC, Avelino-Cruz JE, Liu N, Persampieri S, Curcio A, Esposito F, Pietrangelo L, Marty I, Villani L, Moyaho A, Baiardi P, Auricchio A, Protasi F, Napolitano C, Priori SG.

Circulation. 2014 Jun 24;129(25):2673-81. doi: 10.1161/CIRCULATIONAHA.113.006901. Epub 2014 Jun 2.

17.

Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.

Pennucci V, Zini R, Norfo R, Guglielmelli P, Bianchi E, Salati S, Sacchi G, Prudente Z, Tenedini E, Ruberti S, Paoli C, Fanelli T, Mannarelli C, Tagliafico E, Ferrari S, Vannucchi AM, Manfredini R; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators.

Leuk Lymphoma. 2015 Feb;56(2):492-6. doi: 10.3109/10428194.2014.910661. Epub 2014 Jun 16. No abstract available.

PMID:
24707949
18.

Pulmonary sequestration: a (131)I whole body scintigraphy false-positive result.

Spinapolice EG, Chytiris S, Fuccio C, Leporati P, Volpato G, Villani L, Trifirò G, Chiovato L.

Ann Nucl Med. 2014 Aug;28(7):683-7.

PMID:
24658773
19.

Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms.

Avanzini MA, Bernardo ME, Novara F, Mantelli M, Poletto V, Villani L, Lenta E, Ingo DM, Achille V, Bonetti E, Massa M, Campanelli R, Fois G, Catarsi P, Gale RP, Moretta A, Aronica A, Maccario R, Acquafredda G, Lisini D, Zecca M, Zuffardi O, Locatelli F, Barosi G, Rosti V; AGIMM Investigators.

Leukemia. 2014 Aug;28(8):1742-5. doi: 10.1038/leu.2014.97. Epub 2014 Mar 12. No abstract available.

PMID:
24618733
20.

Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling.

Eterno V, Zambelli A, Pavesi L, Villani L, Zanini V, Petrolo G, Manera S, Tuscano A, Amato A.

Oncotarget. 2014 Feb 15;5(3):613-33.

Supplemental Content

Loading ...
Support Center